AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11072435
Drug: 15-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-mg nicotine patch (Nicotrol)
Trial: 11072435
Drug: 21-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21-mg nicotine patch (Nicoderm)
Trial: 11072435
Drug: Both nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both nicotine patches (Nicotrol and Nicoderm)
Trial: 7540147
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (historical control group)
Trial: 2025787
Drug: Gemfibrozil treatment
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil treatment for 12 months
Trial: 6617110
Drug: Hydrochlorothiazide-spironolactone combination
RxNorm normalized name: hydrochlorothiazide / spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide-spironolactone combination (25 mg B.I.D.)
Trial: 6617110
Drug: Hydrochlorothiazide-spironolactone combination
RxNorm normalized name: hydrochlorothiazide / spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide-spironolactone combination (50 mg O.I.D.)
Trial: 30022362
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV paracetamol 1000 mg in 100 ml solution (Group P)
Trial: 30022362
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen 800 mg in 100 ml saline (Group I)
Trial: 30022362
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group C, 100 ml saline solution)
Trial: 18848553
Drug: adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab 40 mg weekly
Trial: 18848553
Drug: adalimumab combined
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: adalimumab combined (every other week and weekly)
Trial: 18848553
Drug: adalimumab weekly
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: adalimumab weekly
Trial: 16038684
Drug: NK1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NK1 antagonist GR205171 (5 mg)
Trial: 12871686
Drug: Nicorandil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (80 g/kg intravenous injection 5 min before ballooning)
Trial: 10475141
Drug: Clinda‐saar 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinda‐saar 600 (test preparation, 600 mg clindamycin)
Trial: 10475141
Drug: Sobelin 300
RxNorm normalized name: lobeline
DrugBank: Lobeline (DB05137)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sobelin 300 (reference preparation, 300 mg clindamycin)
Trial: 1831340
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous administration of CI-898 at 15 mg/m2
Trial: 1831340
Drug: 5-day intravenous
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-day intravenous administration of CI-898 starting at 10 mg/m2/day
Trial: 1831340
Drug: 5-day intravenous
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-day intravenous administration of CI-898
Trial: 1831340
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment of CI-898
Trial: 1831340
Drug: 5-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day treatment of CI-898
Trial: 29901443
Drug: Drug‐eluting stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug‐eluting stents with bioabsorbable polymers (BP‐DES)
Trial: 27598678
Drug: BDP/FF/GB (beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/GB (beclometasone dipropionate 100 μg, formoterol fumarate 6 μg, glycopyrronium bromide 12.5 μg)
Trial: 27598678
Drug: BDP/FF (beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF (beclometasone dipropionate 100 μg, formoterol fumarate 6 μg)
Trial: 22515897
Drug: NovaMin paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovaMin paste treatment for 5 minutes (Group A)
Trial: 20560802
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg daily for a maximum of 4 weeks)
Trial: 20560802
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (pain-relieving therapy only)
Trial: 17697874
Drug: Tesaglitazar 3
RxNorm normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesaglitazar 3 mg
Trial: 15578172
Drug: S‐omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐omeprazole (20 mg)
Trial: 15578172
Drug: R‐omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐omeprazole (20 mg)
Trial: 15578172
Drug: Racemic omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Racemic omeprazole (20 mg)
Trial: 15578172
Drug: S‐omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐omeprazole (40 mg)
Trial: 15578172
Drug: R‐omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐omeprazole (40 mg)
Trial: 15578172
Drug: Racemic omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Racemic omeprazole (40 mg)
Trial: 9933654
Drug: 153Sm-EDTMP at
RxNorm normalized name: 153SM-EDTMP
DrugBank: Samarium (153Sm) lexidronam (DB05273)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 153Sm-EDTMP at a dose of 37 MBq/kg (group I)
Trial: 9933654
Drug: 153Sm-EDTMP at
RxNorm normalized name: 153SM-EDTMP
DrugBank: Samarium (153Sm) lexidronam (DB05273)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 153Sm-EDTMP at a dose of 18.5 MBq/kg (group II)
Trial: 12690546
Drug: Piperacillin-tazobactam (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam (4.5 g every 8 h)
Trial: 12690546
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g once daily plus gentamicin 5 mg/kg once daily)
Trial: 1489202
Drug: 1-hour infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusions of amphotericin B (AMB) at doses ranging from 0.27 to 0.89 mg/kg
Trial: 1489202
Drug: 1-hour infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusions of amphotericin B (AMB)
Trial: 26372517
Drug: Bifidobacterium animalis
RxNorm normalized name: Bifidobacterium Animalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium animalis subsp. lactis BB-12 (BB-12) administered twice a day (daily dose of BB-12 10 billion colony-forming units) until the age of 2 years.
Trial: 25981123
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (±glulisine)
Trial: 16707077
Drug: Glycerol trinitrate
RxNorm normalized name: Glycerol trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol trinitrate (GTN) patches
Trial: 16707077
Drug: Standard beta2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard beta2 agonist
Trial: 15265423
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with omeperazole, clarithromycin (CLA), and amoxycillin (AMO) for one week (CLA group)
Trial: 15265423
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with omeperazole, metronidazole (MET), and amoxycillin (AMO) for two weeks (MET group)
Trial: 15265423
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with CLA triple therapy for one week after failure of MET therapy
Trial: 15265423
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with increased doses of CLA and longer treatment course after failure of CLA therapy
Trial: 15265423
Drug: Tetra therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetra therapy with omeperazole, colloidal bismuth subcitrate (CBS), furazolidone (FUR), and AMO after failure of re-treatment
Trial: 15265423
Drug: CLA triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLA triple therapy for children who were Hp eradicated and followed for 3 years
Trial: 8028874
Drug: Medications with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications with hyaluronidase
Trial: 817384
Drug: 2% solution
RxNorm normalized name: Lidomar 2% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% solution of sodium cromoglycate (S.C.G.)
Trial: 29165105
Drug: TTM-based educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTM-based educational program including motivational interviewing, a booklet, and daily SMS.
Trial: 20806131
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation therapy with subsequent surgery (control arm)
Trial: 12566906
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) 10,000 U thrice weekly s.c.
Trial: 9078647
Drug: Active dentifrice
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active dentifrice and oral rinse containing sanguinaria extract and zinc chloride
Trial: 9078647
Drug: Placebo dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dentifrice and oral rinse
Trial: 8103272
Drug: Topical cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporin A (8% w/v) with penetration enhancers (propylene glycol 18% and azone 2%)
Trial: 8103272
Drug: Topical cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporin A (8% w/v)
Trial: 3714757
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tiropramide
Trial: 3714757
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg trimebutine maleate
Trial: 3714757
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg octilonium bromide
Trial: 30203841
Drug: Avatrombopag 20
RxNorm normalized name: avatrombopag 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avatrombopag 20 mg daily for 14 days
Trial: 30203841
Drug: Avatrombopag (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avatrombopag (1, 3, 10, 20, 50, 75 and 100 mg)
Trial: 30203841
Drug: Avatrombopag (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avatrombopag (3, 10 and 20 mg)
Trial: 26321236
Drug: Pooled pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled pacing therapy
Trial: 23889105
Drug: 2 g intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g intravenous Cefazoline administered prior to skin incision
Trial: 23889105
Drug: 2 g intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g intravenous Cefazoline administered immediately after cord clamping
Trial: 22134627
Drug: Polysporin Triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysporin Triple ointment (P(3))
Trial: 18097177
Drug: Orbital radiotherapy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital radiotherapy combined with oral corticosteroids
Trial: 18097177
Drug: Orbital radiotherapy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital radiotherapy combined with intravenous methylprednisolone
Trial: 15966883
Drug: AmF/SnF(2) dentifrice-mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF/SnF(2) dentifrice-mouth rinse combination
Trial: 10471987
Drug: Cisapride with
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisapride with Pantoprazole (40 mg)
Trial: 8335505
Drug: IFN-alpha priming
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha priming followed by IFN-alpha therapy (10 MU thrice-weekly for three months)
Trial: 8335505
Drug: IFN-alpha therapy
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha therapy (10 MU thrice-weekly for three months)
Trial: 3743147
Drug: Instillation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of 50 ml of 0.1 N hydrochloric acid in Group 3
Trial: 3743147
Drug: Atropine pretreatment
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine pretreatment (0.01 mg/kg twice daily) followed by instillation of acid in Group 3
Trial: 3743147
Drug: Instillation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of 50 ml of isotonic sodium chloride solution
Trial: 30863141
Drug: Methoxyflurane (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxyflurane (up to 6 mL)
Trial: 22679908
Drug: Tianeptine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (37.5 mg) with probiotics (Bacillus subtilis + Streptococcus faecium)
Trial: 22679908
Drug: Amitriptyline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (10 mg) with probiotics (Bacillus subtilis + Streptococcus faecium)
Trial: 20081065
Drug: Single ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose (SAD) of edoxaban (10, 30, 60, 90, 120, 150 mg)
Trial: 20081065
Drug: Multiple ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose (MAD) of edoxaban (90 mg daily, 60 mg twice daily, 120 mg daily)
Trial: 15951655
Drug: Tiagabine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (maximum dose 24 mg/day)
Trial: 11251695
Drug: Gabapentin (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (2400 mg/day)
Trial: 8934107
Drug: 2500 XaI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2500 XaI units of low molecular weight heparin daily
Trial: 8934107
Drug: 5000 XaI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 XaI units of low molecular weight heparin daily
Trial: 1930768
Drug: Methanol exposure
RxNorm normalized name: methanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methanol exposure at 250 mg/m3 for 75 minutes
Trial: 6131124
Drug: Using psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using psychotropic drugs (benzodiazepines)
Trial: 31123862
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g bovine colostrum for 4.5 hours
Trial: 31123862
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g bovine colostrum per day for 4 weeks
Trial: 31123862
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g bovine colostrum per day for 12 weeks
Trial: 31271359
Drug: Reduced unit
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced unit dose of rabies immunoglobulin (RIG) for class 3 rabid animal bites
Trial: 17552299
Drug: Conventional restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional restorative treatment using rotary instruments (750 rpm)
Trial: 15117306
Drug: Pyrimethamine-sulphadoxine plus
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine-sulphadoxine plus probenecid (20-25 mg/kg in two divided doses daily for 3 days)
Trial: 15117306
Drug: Pyrimethamine-sulphadoxine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine-sulphadoxine (25 mg/kg of the sulphadoxine component)
Trial: 7803248
Drug: IVIg 500
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg 500 mg/kg every 4 weeks for 1 year
Trial: 7803248
Drug: IVIg 250
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg 250 mg/kg every 4 weeks for 1 year
Trial: 31553946
Drug: 5A's model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5A's model for PA counseling with weekly motivational text messages
Trial: 16430010
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L‐Pop
Trial: 17159028
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for glaucoma (cataract extraction)
Trial: 17159028
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for glaucoma
Trial: 12897178
Drug: L-NAME (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME (4 mg kg-1 in 50 ml saline over 60 min)
Trial: 12897178
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without L-NAME)
Trial: 1528102
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA (IPCA)
Trial: 30975627
Drug: Erlotinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib plus bevacizumab (150 mg per day erlotinib + 15 mg/kg bevacizumab once every 21 days)
Trial: 30975627
Drug: Erlotinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib alone (150 mg per day)
Trial: 29905969
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation, adjusted to maintain serum 25(OH)D above 75 nmol/L
Trial: 26725183
Drug: Pemetrexed plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed plus Cisplatin followed by Gefitinib (PC/G)
Trial: 26809984
Drug: Gefitinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib monotherapy (G)
Trial: 25168762
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sports-oriented exercise programme and web-delivered self-help tool
Trial: 22442436
Drug: Pulsed dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pulsed dexamethasone (6 monthly pulses)
Trial: 22442436
Drug: Daily prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisolone (8 months)
Trial: 22442436
Drug: Daily prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisolone
Trial: 22442436
Drug: None (treatment-nonresponsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None (treatment-nonresponsive patients)
Trial: 17700050
Drug: Brief Dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Dynamic Therapy (BDT) combined with antidepressants
Trial: 17700050
Drug: Supportive Psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Psychotherapy (BSP) combined with antidepressants
Trial: 11820944
Drug: Albuterol +
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol + Ipratropium
Trial: 8674228
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (200 micrograms applied to one nostril daily for 3 weeks)
Trial: 8674228
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (200 micrograms applied to one nostril daily for 3 weeks)
Trial: 21077346
Drug: Nifedipine CR
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine CR (NCR) dose uptitration (VAL 80 mg + NCR 40 mg)
Trial: 21077346
Drug: Valsartan (VAL)
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan (VAL) dose uptitration (VAL 160 mg + NCR 20 mg)
Trial: 21077346
Drug: Nifedipine CR
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine CR (NCR) dose uptitration
Trial: 21077346
Drug: Valsartan (VAL)
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan (VAL) dose uptitration
Trial: 17568867
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg/day for three days, n = 49)